Examination Survey (NHANES; 1988. We quantified recent trends for 6 metrics (total cholesterol, systolic blood pressure, physical inactivity, smoking, diabetes mellitus, and obesity) and generated linear projections to 2020. We projected the expected number of CHD deaths in 2020 if 2006 age-and sex-specific CHD death rates remained constant, which would result in ≈480 000 CHD deaths in 2020 (12% increase). We used the previously validated IMPACT CHD model to project numbers of CHD deaths in 2020 under 2 different scenarios: (1) Assuming a 20% improvement in each cardiovascular health metric, we project 365 000 CHD deaths in 2020 (range 327 000-403 000) a 24% decrease reflecting modest reductions in total cholesterol (−41 000), systolic blood pressure (−36 000), physical inactivity (−12 000), smoking (−10 000), diabetes mellitus (−10 000), and obesity (−5000); (2) Assuming that recent risk factor trends continue to 2020, we project 335 000 CHD deaths (range 274 000-386 000), a 30% decrease reflecting improvements in total cholesterol, systolic blood pressure, smoking, and physical activity (≈167 000 fewer deaths), offset by increases in diabetes mellitus and body mass index (≈24 000 more deaths). Conclusions-Two contrasting scenarios of change in cardiovascular health metrics could prevent 24% to 30% of the CHD deaths expected in 2020, though with differing effects by age. Unfavorable continuing trends in obesity and diabetes mellitus would have substantial adverse effects. This analysis demonstrates the utility of modelling to inform health policy. The online-only Data Supplement is available with this article at http://circ.ahajournals.org/lookup/suppl/
C ardiovascular disease (CVD) death rates have fallen dramatically in the United States since the 1960s. 1, 2 Our previous work indicates that these mortality declines reflect both decreases in population risk factor levels (attributable to public health, environmental, and behavioral changes) and clinical application of evidence-based therapies. 3 However, CVD remains the leading cause of US mortality, accounting for nearly 800 000 deaths and 6 million hospital discharges annually. 2 Previously falling CVD death rates have now plateaued in younger adults, and obesity and diabetes mellitus are increasing. 2, 4 If these adverse trends continue, the annual direct US costs of CVD could reach $820 billion by 2030. 5 
Clinical Perspective on p 2484
In response to these trends, the American Heart Association (AHA) has recently defined and outlined its 2020 Strategic Impact Goal of achieving a 20% reduction in cardiovascular and stroke deaths and a 20% improvement in cardiovascular health (CVH) of all Americans by 2020. CVH is defined in terms of 7 metrics: 4 health behaviors (smoking, diet, physical activity, body mass index [BMI]) and 3 health factors (plasma glucose, cholesterol, blood pressure). 6 Numerous studies have affirmed the relevance of this new CVH paradigm through their description of a robust, stepwise association between greater levels of CVH and lower event rates, including ischemic heart disease, cardiovascular disease, and all-cause mortality 7, 8 and nonfatal CVD events. [9] [10] [11] We recently projected forward, linear trends using National Health and Nutrition Examination Survey (NHANES) data in each of these metrics to 2020 and estimated that if current trends were to continue unaltered, CVH would improve by only 6%. 12 June 25, 2013
We have previously used our US IMPACT CHD policy model to explain trends in CHD mortality between 1980 and 2000 3 and to project future trends in CHD mortality. 13 In the present study, we sought to estimate potential reductions in CHD mortality by 2020 under 2 contrasting risk factor scenarios: (1) assuming a 20% relative improvement in each of 6 metrics (diet score excluded because of modeling limitations), and (2) assuming that recent trends in these CVH metrics continue.
Methods

The US IMPACT CHD Model
The US IMPACT CHD Model is a spreadsheet-based model that uses epidemiological data and extensive systematic literature reviews to quantify estimates of CHD mortality based on evidencebased medical and procedural treatments and population risk factor reductions under operator-defined scenarios. 3 It was developed to help explain population-level changes in CHD death rates over time. The model includes >60 covariates overall, 6 of which serve to quantify changes in population levels of health behaviors and factors, specifically smoking, cholesterol, blood pressure, BMI, diabetes mellitus, and physical inactivity (6 of the 7 metrics for measurement of CVH, as defined by the American Heart Association [see online-only Data Supplement for definitions of CVH metrics]). The model also includes >50 covariates that can quantify changes in standard medical treatments, such as acute therapies for myocardial infarction including aspirin, β blockers, statins, heparin, thrombolysis, percutaneous coronary intervention, and coronary artery bypass graft surgery, as well as chronic drug therapies for primary and secondary prevention therapy with aspirin, statins, and blood pressurelowering therapies.
The IMPACT CHD model uses β coefficients derived from large meta-analyses to provide effect size estimates for continuous variables (blood pressure [per 20-mm Hg change], cholesterol [per 1 mmol/L change], and BMI [per 1 kg/m 2 change]). Coefficients are assumed to be independent because previous meta-analyses used as data sources adjusted for potential confounders, including other major risk factors. For each continuously distributed risk factor, changes in mortality from 2006 to 2020 could be estimated by multiplying 3 variables:
Number of CHD deaths
attributable to RF = CHD deaths × the risk factor change × specific regression coefficient exponentiated 3, [14] [15] [16] [17] The IMPACT CHD model uses population-attributable risk fraction effect size estimates for prevalence, or categorical variables such as smoking, diabetes mellitus, or physical inactivity to evaluate the impact of changes in these variables on CHD death. [15] [16] [17] The population-attributable risk fraction estimates for CHD are based on data from the INTERHEART study, which accounted for potential confounders. Changes in mortality from the base year used by the AHA Strategic Impact Goals committee (2006) to 2020 for each prevalence variable were calculated:
Number of CHD deaths attributable of RF = CHD deaths × [P × (RR − 1) ⁄ [1 + P (RR − 1)],
where P = prevalence change of risk factors and RR = relative risk of CHD death.
For example, for men between the ages of 65 and 74 years, the odds ratio associated with CHD death is 2.52, the smoking prevalence in 2005 to 2006 was 14.7%, and the number of CHD deaths was 42 848 deaths. Using the above formula, the estimated number of CHD deaths in 2006 attributable to smoking is as follows: The difference between 2020 and 2006 attributable deaths for each variable is taken to estimate the number of deaths prevented or postponed (DPPs). Total deaths from changes in categorical variables can then be summed to provide an estimate of deaths prevented or postponed for comparison with the reference estimate that accounts for population aging, without any change in risk factors or medical or surgical treatments.
For the present analysis, we first extended the original 1980 to 2000 US IMPACT CHD model to 2020, using United States Census Bureau population projections and mortality data for men and women aged 25 to 85+ years. The number of CHD deaths (International Classification of Diseases, ICD-10: I20-I25) expected in 2020 was calculated under baseline conditions, assuming that the age-specific mortality rates in 2006 persisted unchanged to 2020. We explored other counterfactual baseline scenarios, such as projecting CHD death rates in a linear fashion to 2020 and by creating hierarchical Bayesian age-period cohort (APC) models to estimate CHD death rates in 2020. These methods produced either implausible (eg, rates below zero) or highly unstable estimates. We chose to use 2006 CHD death rates based on these limitations and for sake of simplicity.
Next, the deaths potentially observed under each of two risk factor scenarios were then estimated as follows.
Risk Factor Scenarios
For Scenario A, representing a 20% improvement in overall CVH, we assumed a 20% improvement in each metric as defined by the AHA using data from 40 373 CVD-free adults (≥20 years) examined in NHANES from 1988 to 2010 (see online-only Data Supplement for participant flowchart). Methods of measurement of each health behavior and health factor have been previously reported and are described in the online-only Data Supplement. We assumed a 20% improvement in categorical variables by decreasing the prevalence of poor CVH by 20% and increasing the prevalence of ideal CVH by 20%. The prevalence of intermediate CVH was then estimated by subtracting the prevalence of poor and ideal health prevalence estimates from 100%.
To estimate a 20% change in a continuous variable such as blood pressure, cholesterol, or BMI in the construct of ideal, intermediate, and poor cardiovascular health categories, we projected a 20% increase in the proportion of individuals in the ideal CVH category and a 20% decrease in the proportion of individuals in the poor CVH category across age and sex strata. We assumed that the mean level of each CVH metric in ideal, intermediate, and poor levels would remain the same, but the projected change in proportion of ideal, intermediate, and poor levels would change the age-and sex-stratified mean level for each CVH metric. This age-and sex-stratified CVH metric mean was then compared against the baseline mean to input into the IMPACT CHD model.
For Scenario B, we assumed that recent risk factor trends would continue to 2020 based on forward linear projections. We quantified recent temporal trends in 6 of 7 CVH metrics by age and sex, using the most recent available data from NHANES (1988-2010). (We could not include the diet score metric because the underlying data are not yet included in the IMPACT Model.) We then generated forward projections to 2020 for population CVH behavior and factor levels. 12 We used 2006 as the base year because the AHA Strategic Impact Goal defines 2006 as its base year.
NHANES trends analyses were performed using SAS v9.1 (SAS Institute, Cary, NC) taking into account the complex sampling design. We estimated time trends from 1988 to 2010 and average annual change in CVH behaviors and factors by weighted linear regression using estimated mean values or percentages as dependent variables and survey times as independent variables, as previously reported. 12 We fitted our regression models with the prevalence as the dependent variables and survey time as independent variables. We used the β coefficients to estimate average annual change in the prevalence of ideal, intermediate, and poor levels of CVH for each metric. We projected estimates to 2020 by assuming that trends would continue similarly to those observed over the past 2 decades in a linear fashion based on standard error (SE) of the predicted prevalence estimates. 12 We used reciprocals of variances as weights. We assessed nonlinear projections, but the results were similar except for blood pressure trends in women, which produced an implausibly low estimate. We chose linear projections for simplicity as in our recently published analyses through 2008. 12 For both scenarios and all sensitivity analyses, we conservatively assumed the prevalence of medical and surgical treatments for CHD would remain constant.
Comparisons of Numbers of Deaths in 2020, With Sensitivity Analyses
Finally, after these steps, we compared the numbers of deaths projected under each Scenario, A and B, with the reference value estimated as above. This included multi-way sensitivity analyses using the analysis of extremes method. 18 We generated minimum and maximum estimates of deaths prevented or postponed using minimum and maximum plausible values for the main parameters: 95% confidence intervals (CIs) when available; otherwise, the best value±20%. Examples of the calculations used in the model and further details on the methods and data sources have been previously reported. 19 
Results
Trends and Estimates in CHD Mortality and Risk Factors
Scenario A: Achieving AHA Strategic Impact Goal through 20% Improvement in Each Metric
A 20% improvement in each metric would result in the following estimates ( Figure 1 ): (1) 41 465 fewer deaths (range, 27 480-58 020) attributable to a 0.18-mmol/L (7.0 mg/dL) decrease in total cholesterol; (2) 36 050 (range, 27 605-42 235) fewer deaths attributable to a 2.8-mm Hg reduction in blood pressure in men and women; (3) 9840 fewer deaths (range, 7870-11 805) attributable to a 4.5% absolute decrease in the prevalence of smoking; (4) 12 295 fewer deaths (range, 9835-14 750) attributable to a 6.5% decrease in the prevalence of physical activity; (5) 4545 fewer deaths (range, 2565-6975) attributable to a 0.9-kg/m2 decrease in mean BMI; and (6) 9670 fewer deaths (range, 165-16 500) attributable to a 1.3% decrease in the prevalence of diabetes mellitus. Altogether, 364 900 CHD deaths (range, 327 470-403 240) would be expected in 2020, under Scenario A, 24% fewer than expected in 2020 under the reference projection.
The 113 860 fewer deaths observed than expected under this scenario would comprise 53 920 fewer deaths (range, 36 145-78 815) in men compared with 59 940 (range, 39 375-76 460) fewer deaths in women ( Table 3 ). The relation of the health factor effects with age is shown in Figure 2 . As would be anticipated, improvements would occur predominantly in older individuals, those aged ≥55 years, because these age groups have the highest number of absolute CHD deaths ( Figure 2 ).
Scenario B: If Current Risk Factor Trends Continue
A continuation of current trends in CVH metrics from 1988 to 2010 projected to 2020 would result in the following estimates ( deaths attributable to a 2.9-mm Hg decrease in systolic blood pressure; (3) 19 455 (range, 15 565-23 345) fewer deaths attributable to a 4.6% decrease in the absolute prevalence of smoking; and (4) 28 430 (range, 22 805-34 585) fewer deaths attributable to a 20.1% decrease in the prevalence of physical inactivity. The adverse trends in body weight and diabetes mellitus would result in 9900 (range, 5,085-14 120) additional deaths attributable to a 1.6-kg/m 2 average increase in BMI; and 14 805 (range, 4,230-19 860) additional deaths attributable to a 2.3% absolute increase in the prevalence of diabetes mellitus. In a secondary analysis, given the instability and implausibility of the estimates for physical inactivity in women, we doubled the 2020 forward projection from 6.7% to 13.4% with minimal change in our overall estimates (data not shown).
Altogether, 335 000 CHD deaths (range, 274 000-386 000) would be expected in 2020, under Scenario B, 30% fewer than expected in 2020 under the reference projection. Approximately 63 010 (range, 41 015-98 525) fewer deaths are estimated in men compared with 80 380 (range, 51 050-115 480) fewer deaths in women (Table 3) . Improvements would again predominantly occur in older individuals aged ≥55 years (Figure 2 ).
Sensitivity Analyses
Using extensive sensitivity analyses, we examined the impact of higher and lower values for model inputs. 18 This changed the absolute number of deaths but not the rank order of benefit across CVH metrics ( Figure 1) : under both scenarios, the biggest projected benefits would consistently come from improvements in cholesterol and blood pressure.
Discussion
These findings suggest that the default projection to 2020 might result in >50 000 additional CHD deaths above the 2006 baseline. Conversely, risk factor improvements among persons with no history of major CVD could in principle reduce CHD deaths in 2020 by 24% to 30% in either of 2 ways. Scenarios A and B both predict major benefits from decreases in population mean values of total cholesterol and systolic blood pressure. Both also include a strong relation between changes in CHD deaths and age, being greater at successively older ages.
Scenario A anticipates a reduction in the prevalence of both obesity and diabetes mellitus whereas Scenario B reasonably predicts an increase, hence the greater overall effect of Scenario A than B in improvement of total cholesterol, systolic blood pressure, smoking, and physical activity. The scenarios also differ in their effect at different ages. The majority of CHD deaths occur in individuals aged >55 years, who currently have more favorable trends in some CVH metrics than do younger individuals (online-only Data Supplement). A 20% reduction for all risk factors (Scenario A) would represent greater improvements at younger ages than has been observed occurred in recent trends. Conversely, continuation of recent trends would have greater effect on older persons at greater CHD risk (Scenario B). This may explain the These results have major implications for both for policy and future research. The policy implications are as follows:
(1) substantial benefit to the US population would be predicted from improvement in CVH metrics from their level in 2006; (2) continuation of recent trends is necessary to have the maximum effect, will chiefly benefit older persons, and warrants strong continuing efforts to sustain those trends; (3) only a policy of improving CVH metrics for all Americans would be expected to reverse the trends in obesity and diabetes mellitus and to confer potential benefit on younger persons. That benefit would be realized increasingly beyond 2020.
Further, the research implications are as follows: (1) analyses using the IMPACT CHD policy model demonstrate the utility of modeling approaches in helping understand how improving CVH of all Americans may effect the second goal of reducing cardiovascular and stroke deaths; (2) broadening the model to encompass other cardiovascular and stroke outcomes and to incorporate dietary components will add importantly to its value; and (3) other alternative scenarios of improving CVH metrics under the AHA 2020 Impact Goal could be similarly explored, further informing critical policy decisions for the nation's health.
These data may provide guidance to the AHA and other policymakers and programs such as the Million Hearts Initiative on how to balance complementary strategies for the dual goal of improving CVH and of reducing CVD deaths. Older individuals have higher absolute risks of CHD death. They might therefore gain greater absolute CHD mortality benefits from both population and high-risk approaches than younger individuals despite similar relative risk reductions. Longerterm gains from improved CVH are expected in younger and middle-aged individuals, because they could realize gains seen in low-risk individuals with optimal health factors 21 and health behaviors 22 over a longer remaining lifespan. However, recent increases in CHD mortality among younger US men and women 4 suggest that some younger individuals might also derive short-term reductions in CHD deaths through improved CVH. 23 Beyond CHD alone, an interaction between CVH and age on CVD mortality has been recently observed, suggesting that ideal CVH may provide greater relative protection against CVD death in younger compared with older Americans. 8 The AHA 2020 Strategic Impact Goal represents an important conceptual step in promoting the concept of CVH. Our data suggest that to reach the 2020 Strategic Impact Goal of improving CVH by 20% while also reducing cardiovascular deaths by at least 20%, the AHA should attempt to augment current, favorable trends in cholesterol and blood pressure, while focusing new efforts on improving trends in BMI, diabetes mellitus, and smoking throughout the lifecourse, which are also drivers of other cardiovascular and noncardiovascular events, including nonfatal myocardial infarction, heart failure, and stroke, which are important end points not evaluated in our US IMPACT CHD model. Therefore, these findings reinforce the concept of a balance between high-risk and populationbased approaches to disease prevention and health promotion, as proposed by Rose. 24 We recognize that a 20% improvement in overall CVH might be more feasibly achieved through other combinations of changes in CVH metrics. For example, if obesity prevalence remains flat (0% change), then a >20% improvement would be needed in other metrics to achieve the AHA's 2020 goal. We anticipate further analyses to explore such alternative scenarios.
Strengths/Limitations
The strengths of our study include the use of nationally representative sample over a 20-year period of data collection and the use of the US IMPACT CHD model. Several limitations should be acknowledged. First, future trends in risk factor levels and prevalences may be nonlinear. Improvements in blood pressure and cholesterol and increases in body weight may be plateauing, 25, 26 whereas the rising obesity epidemic may unfavorably alter trends in other metrics. Second, physical activity measures are particularly susceptible to sampling variability, so projections (particularly in women) should be treated cautiously. Third, the IMPACT CHD model evaluates CHD death and does not consider nonfatal events such as myocardial infarction, stroke, and heart failure. These nonfatal events are potentially important targets of prevention, particularly in younger individuals. Fourth, the IMPACT CHD model is relatively simple and requires rigorous sensitivity analyses that are reflected in the wide confidence intervals. Fifth, the IMPACT CHD model does not incorporate diet, but does quantify the major downstream consequences of diet (blood pressure, cholesterol, BMI, and diabetes mellitus), which are more proximal risk factors for CHD death.
Conclusions
Successfully achieving AHA 2020 CVH targets through a 20% improvement in each of 6 CVH metrics could prevent ≈24% of CHD deaths expected in 2020. Similar reductions in CHD deaths may occur if current trends in these CVH metrics continue. However, unfavorable trends in some CVH metrics may lead to increased rates of adverse cardiovascular outcomes and deaths, particularly over a longer time horizon. This analysis demonstrates the utility of modelling approaches to inform health policy. 
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